Carl W. Langren's most recent trade in Lumos Pharma Inc was a trade of 683 Common Stock done at an average price of $12.3 . Disclosure was reported to the exchange on April 1, 2021.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Lumos Pharma Inc | Carl W. Langren | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.25 per share. | 01 Apr 2021 | 683 | 11,494 (0%) | 0% | 12.3 | 8,367 | Common Stock |
Lumos Pharma Inc | Carl W. Langren | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 11,475 | 11,475 | - | - | Stock Option (Right to Buy) | |
Lumos Pharma Inc | Carl W. Langren | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 939 | 12,177 (0%) | 0% | 0 | Common Stock | |
Lumos Pharma Inc | Carl W. Langren | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
Lumos Pharma Inc | Carl W. Langren | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 9,000 | 11,238 (0%) | 0% | 0 | Common Stock |